Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells
Ovarian cancer (OC) is the leading cause of gynecological cancer-related death in North America. Most ovarian cancer patients (OCPs) experience disease recurrence after first-line surgery and chemotherapy; thus, there is a need for novel second-line treatments to improve the prognosis of OC. Although peripheral blood-derived NK cells are known for their ability to spontaneously lyse tumour cells without prior sensitization, ascites-derived NK cells (ascites-NK cells) isolated from OCPs exhibit inhibitory phenotypes, impaired cytotoxicity and may play a pro-tumourigenic role in cancer progression. Therefore, it is of interest to improve the cytotoxic effector function of impaired OCP ascites-NK cells at the tumour environment. We investigated the efficacy of using an artificial APC-based ex vivo expansion technique to generate cytotoxic, expanded NK cells from previously impaired OCP ascites-NK cells, for use in an autologous model of NK cell immunotherapy. We are the first to obtain a log-scale expansion of OCP ascites-NK cells that upregulate the surface expression of activating receptors NKG2D, NKp30, NKp44, produce robust amounts of anti-tumour cytokines in the presence of OC cells and mediate direct tumour cytotoxicity against ascites-derived, primary OC cells obtained from autologous patients. Our findings demonstrate that it is possible to generate cytotoxic OCP ascites-NK cells from previously impaired OCP ascites-NK cells, which presents a promising immunotherapeutic target for the second-line treatment of OC. Future work should focus on evaluating the in vivo efficacy of autologous NK cell immunotherapy through the intraperitoneal delivery of NK cell expansion factors to a preclinical xenograft mouse model of human OC.
KeywordsOvarian cancer Natural killer cell cancer immunotherapy Ex vivo NK cell expansion Ascites Autologous natural killer cells
Artificial antigen-presenting cell
Carboxyfluorescein succinimidyl ester
- NK cells
Natural killer cells
Ovarian cancer patient
- OCP ascites-NK cells
NK cells derived from ovarian cancer patient ascites
- PB-NK cells
NK cells derived from peripheral blood
Tumor necrosis factor-α
Vascular endothelial growth factor
We thank Dr. Karen Mossman for providing us with the OVCAR-8 cell line. We also thank Jann Ang and Natasha Kazhdan for aiding us in sample collection.
Funding for this research was supported by grants from the Juravinski Hospital and Cancer Centre Foundation, the Canadian Breast Cancer Foundation and the Canadian Institutes of Health Research Tier 1 Canada Research Chair awarded to Dr. Ali A. Ashkar.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Cell line authentication
The OVCAR-8 cell line was verified using the American Type Culture Collection® (ATCC®) Cell Line Authentication Service for which we received a Short Tandem Repeat Profile Report on September 5, 2017. The submitted OVCAR-8 sample is an exact match to the short tandem repeat profile for the cell line OVCAR-8 listed on the Expasy website: http://web.expasy.org/cellosaurus/CVCL_1629.
- 2.Statistics CCSsACoC (2016) Canadian Cancer Statistics 2016. Government of Canada. http://www.cancer.ca/~/media/cancer.ca/CW/cancerinformation/cancer 101/Canadian cancer statistics/Canadian-Cancer-Statistics-2016-EN.pdf?la = en. Accessed 26 Nov 2016
- 4.Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J (2004) Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 22(15):3120–3125. https://doi.org/10.1200/JCO.2004.05.195 CrossRefPubMedGoogle Scholar
- 6.Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic Oncology G (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194–3200. https://doi.org/10.1200/JCO.2003.02.153 CrossRefPubMedGoogle Scholar
- 12.Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS (2011) A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13(1):98–107. https://doi.org/10.3109/14653249.2010.515582 CrossRefPubMedGoogle Scholar
- 13.Geller MA, Knorr DA, Hermanson DA, Pribyl L, Bendzick L, McCullar V, Miller JS, Kaufman DS (2013) Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. Cytotherapy 15(10):1297–1306. https://doi.org/10.1016/j.jcyt.2013.05.022 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Lutgendorf SK, Sood AK, Anderson B, McGinn S, Maiseri H, Dao M, Sorosky JI, De Geest K, Ritchie J, Lubaroff DM (2005) Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol 23(28):7105–7113. https://doi.org/10.1200/JCO.2005.10.015 CrossRefPubMedGoogle Scholar
- 21.Belisle JA, Gubbels JA, Raphael CA, Migneault M, Rancourt C, Connor JP, Patankar MS (2007) Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology 122(3):418–429. https://doi.org/10.1111/j.1365-2567.2007.02660.x CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, Ljunggren HG, Kiessling R, Malmberg KJ (2009) Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol 183(8):4921–4930. https://doi.org/10.4049/jimmunol.0901226 CrossRefPubMedGoogle Scholar
- 24.Pesce S, Tabellini G, Cantoni C, Patrizi O, Coltrini D, Rampinelli F, Matta J, Vivier E, Moretta A, Parolini S, Marcenaro E (2015) B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. Oncoimmunology 4(4):e1001224. https://doi.org/10.1080/2162402X.2014.1001224 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Tabellini G, Benassi M, Marcenaro E, Coltrini D, Patrizi O, Ricotta D, Rampinelli F, Moretta A, Parolini S (2014) Primitive neuroectodermal tumor in an ovarian cystic teratoma: natural killer and neuroblastoma cell analysis. Case Rep Oncol 7(1):70–78. https://doi.org/10.1159/000357802 CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Lukesova S, Vroblova V, Tosner J, Kopecky J, Sedlakova I, Cermakova E, Vokurkova D, Kopecky O (2015) Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma. Contemp Oncol (Pozn) 19(4):290–299. https://doi.org/10.5114/wo.2015.54388 Google Scholar
- 30.Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH, Champlin RE, Cooper LJ, Lee DA (2012) Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 7(1):e30264. https://doi.org/10.1371/journal.pone.0030264 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ (2013) Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 8(10):e76781. https://doi.org/10.1371/journal.pone.0076781 CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Oyer JL, Igarashi RY, Kulikowski AR, Colosimo DA, Solh MM, Zakari A, Khaled YA, Altomare DA, Copik AJ (2015) Generation of highly cytotoxic natural killer cells for treatment of acute myelogenous leukemia using a feeder-free, particle-based approach. Biol Blood Marrow Transplant 21(4):632–639. https://doi.org/10.1016/j.bbmt.2014.12.037 CrossRefPubMedGoogle Scholar
- 34.Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T, Schaap N, Dolstra H (2011) Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One 6(6):e20740. https://doi.org/10.1371/journal.pone.0020740 CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, Moretta L, Moretta A, Marcenaro E (2017) Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J Allergy Clin Immunol 139(1):335–346 e333. https://doi.org/10.1016/j.jaci.2016.04.025 CrossRefPubMedGoogle Scholar
- 38.Gubbels JA, Felder M, Horibata S, Belisle JA, Kapur A, Holden H, Petrie S, Migneault M, Rancourt C, Connor JP, Patankar MS (2010) MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer 9:11. https://doi.org/10.1186/1476-4598-9-11 CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T, Robinson SC, Gallagher WM, Galletta L, Australian Ovarian Cancer Study G, Salako MA, Smyth JF, Hagemann T, Brennan DJ, Bowtell DD, Balkwill FR (2012) A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res 72(1):66–75. https://doi.org/10.1158/0008-5472.CAN-11-2178 CrossRefPubMedGoogle Scholar
- 43.Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT et al (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313(23):1485–1492. https://doi.org/10.1056/NEJM198512053132327 CrossRefPubMedGoogle Scholar